Agios Pharmaceuticals (AGIO)
NASDAQ:AGIO
Want to see AGIO full AI Analyst Report?
AGIO Stock Chart & Stats
$35.14
-$0.03(-0.09%)
At close: 4:00 PM EST
$35.14
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume212.48K
Average Volume (3M)1.15M
Market Cap
$1.81B
Enterprise Value$1.67B
Total Cash (Recent Filing)$737.04M
Total Debt (Recent Filing)$35.74M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Jul 30, 2026EPS Estimate
-1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.25
Shares Outstanding59,471,607
10 Day Avg. Volume758,339
30 Day Avg. Volume1,149,927
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue25.29
Enterprise Value/Gross Profit30.82
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$39.20Price Target Upside11.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-6.13
Revenue Forecast (FY)$91.59M
Bulls Say, Bears Say
Bulls Say
Launch ExecutionEarly, rapid prescriber adoption and a functioning REMS demonstrate Agios can operationalize specialty launches and patient support. That capability underpins durable commercial scalability for mitapivat across hematology indications and supports repeatable rollouts in other markets and indications.
Revenue Growth & MarginsHigh gross margins and sustained revenue growth indicate a scalable product economics profile typical of specialty therapies. As volume builds, margins support funding R&D and commercial investment and improve the pathway to positive cash generation if uptake continues and operating spend stabilizes.
Balance Sheet LiquidityA >$1B liquidity cushion and low leverage provide multi-quarter runway to fund launches, confirmatory trials, and pipeline programs without immediate refinancing. This financial flexibility materially reduces near-term solvency risk while the company pursues regulatory and commercial milestones.
Bears Say
Persistent Cash BurnSustained, large negative operating and free cash flow requires ongoing financing or rapid revenue scaling. Persistent burn limits optionality, raises dilution risk, and forces prioritization across programs, constraining long-term investment flexibility if commercial traction slows.
Pipeline SetbackDiscontinuing tebapivat in LR-MDS reduces future addressable revenue and removes a potential near-term approval catalyst. This loss narrows the pipeline's breadth, forces resource reallocation, and diminishes the long-term diversification of revenue streams anchored by mitapivat.
Regulatory & Access RequirementsReliance on an accelerated approval path with a required confirmatory trial creates durable regulatory execution risk and timing uncertainty. Even if granted, payer policy rollouts and confirmatory outcomes will materially affect durable uptake and revenue realization over multiple quarters.
Agios Pharma News
AGIO FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $1.81B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 60 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Apr 29, 2026. The company reported -$1.69 earnings per share for the quarter, beating the consensus estimate of -$1.803 by $0.113.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.61.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 59,471,607 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.69 in its last earnings report, beating expectations of -$1.803. Following the earnings report the stock price went up 13.105%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.20 (11.55% Upside)
$39.20 (11.55% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 388.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $152.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Bullish
Bullish news 79%
Bearish news 38%
Bearish news 38%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.66%
12-Months-Change
Fundamentals
Return on Equity
-34.11%
Trailing 12-Months
Asset Growth
-23.82%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong early commercial momentum and significant regulatory and pipeline progress—highlighted by 138% YoY revenue growth, a successful AQVESME U.S. launch with 242 prescriptions, planned sNDA submission for mitapivat in sickle cell disease, and a robust cash position (> $1B). Offsetting items included rising R&D and SG&A spend, limited ex‑U.S. revenue and quarter‑to‑quarter variability, a prescription‑to‑initiation lag as launch broadens, a 60% lower tebapivat exposure signal in low‑risk MDS necessitating higher‑dose evaluation, and some regulatory/competitive uncertainty that will need to be resolved by upcoming data and confirmatory trials. Overall, the positives (strong growth, launch execution, regulatory progress and ample liquidity) materially outweigh the near‑term challenges and risks.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$39.20
▲(11.55% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
1.11% Insiders
25.86% Mutual Funds
51.63% Other Institutional Investors
1.60% Public Companies and
Individual Investors